clinical trial · NCT06540144
An Extension Study Evaluating 6-week Treatment Cycles of Rozanolixizumab in Pediatric Study Participants With Generalized Myasthenia Gravis
UCB Biopharma SRL·phase3·active not recruiting·n = 13
Generalized Myasthenia Gravisrozanolixizumab
brief summary
The purpose of the study is to assess the long term safety and tolerability of additional 6-week treatment cycles with rozanolixizumab in pediatric participants with generalized Myasthenia Gravis (gMG) aged ≥2 at the time of the Screening Visit of MG0006.
started
Oct 8, 2024
primary completion
Oct 5, 2027
completion
Oct 5, 2027
last updated
Oct 16, 2026
official title
An Open-label Extension Study to Evaluate Rozanolixizumab in Pediatric Study Participants With Generalized Myasthenia Gravis
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol